SGMO Sangamo Therapeutics Inc

Price (delayed)

$9.94

Market cap

$1.43B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.88

Enterprise value

$1.34B

Highlights
The revenue is up by 22% year-on-year and by 11% since the previous quarter
The gross profit rose by 22% YoY and by 11% QoQ
The equity rose by 19% YoY but it fell by 6% QoQ
The EPS has declined by 7% year-on-year but it is up by 2.2% since the previous quarter
Sangamo Therapeutics's net income has decreased by 29% YoY and by 2.5% QoQ
The quick ratio has declined by 24% year-on-year

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
143.88M
Market cap
$1.43B
Enterprise value
$1.34B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.03
Price to sales (P/S)
10.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.23
Earnings
Revenue
$131.4M
EBIT
-$123.41M
EBITDA
-$109.34M
Free cash flow
$101.33M
Per share
EPS
-$0.88
Free cash flow per share
$0.71
Book value per share
$3.28
Revenue per share
$0.92
TBVPS
$5.45
Balance sheet
Total assets
$877.1M
Total liabilities
$407.68M
Debt
$38.46M
Equity
$470.36M
Working capital
$474.11M
Liquidity
Debt to equity
0.08
Current ratio
4.57
Quick ratio
4.48
Net debt/EBITDA
0.79
Margins
EBITDA margin
-83.2%
Gross margin
100%
Net margin
-94.4%
Operating margin
-100%
Efficiency
Return on assets
-13.5%
Return on equity
-24.8%
Return on invested capital
-25.2%
Return on capital employed
-16.6%
Return on sales
-93.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
-2.17%
1 week
1.22%
1 month
-14.46%
1 year
-10.05%
YTD
-36.32%
QTD
-16.96%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$131.4M
Gross profit
$131.4M
Operating income
-$131.33M
Net income
-$124.02M
Gross margin
100%
Net margin
-94.4%
Sangamo Therapeutics's net income has decreased by 29% YoY and by 2.5% QoQ
The operating income has contracted by 24% YoY
The revenue is up by 22% year-on-year and by 11% since the previous quarter
The gross profit rose by 22% YoY and by 11% QoQ

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
3.03
P/S
10.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.23
The EPS has declined by 7% year-on-year but it is up by 2.2% since the previous quarter
The equity rose by 19% YoY but it fell by 6% QoQ
The price to book (P/B) is 16% lower than the 5-year quarterly average of 3.7 and 6% lower than the last 4 quarters average of 3.3
The stock's P/S is 41% below its 5-year quarterly average of 18.7 and 14% below its last 4 quarters average of 12.9
The revenue is up by 22% year-on-year and by 11% since the previous quarter

Efficiency

How efficient is Sangamo Therapeutics business performance
The company's return on assets rose by 11% YoY and by 6% QoQ
The ROE has contracted by 9% YoY
The return on sales is up by 8% since the previous quarter but it has declined by 5% year-on-year
Sangamo Therapeutics's return on invested capital has increased by 7% QoQ but it has decreased by 3.7% YoY

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 115% greater than its total liabilities
SGMO's total liabilities has surged by 115% year-on-year but it is down by 8% since the previous quarter
SGMO's total assets has surged by 50% year-on-year but it is down by 7% since the previous quarter
SGMO's debt is 92% lower than its equity
Sangamo Therapeutics's debt to equity has decreased by 20% YoY
The equity rose by 19% YoY but it fell by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.